netFormulary North of Tyne and Gateshead Area Prescribing Committee NHS
Formulary  
 Search
 Formulary Chapter 13: Skin - Full Chapter
Notes:

North of Tyne and Gateshead Guidelines for the Management of Acne (from 12 years of age)

 Details...
13.05.03  Expand sub section  Drugs affecting the immune response
Adalimumab (Humira®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for psoriasis in line with NICE.
  • Approved for the treatment of moderate to severe hidradenitis suppurativa in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
 
Link  NICE TA146 Adalimumab for the treatment of adults with psoriasis
Link  NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Apremilast (Otezla®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 10mg, 20mg & 30mg tablets
  • To be used in accordance with NICE guidance
 
Link  NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
   
Brodalumab (Kyntheum® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG

 

  • 210mg/1.5ml solution for injection in pre-filled syringes.
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE 

 

 
Link  NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
   
Ciclosporin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
  • Capsules & SF Solution 
    See section 8.2.2
 
   
Dimethyl fumarate (Skilarence®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 120mg tablets
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
 
Link  NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
   
Etanercept (Enbrel®, Benapali® & Erelzi®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for psoriasis in line with NICE
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
 
Link  NICE TA103: Psoriasis - efalizumab and etanercept
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
Guselkumab (Tremfya®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
  • 100mg/1mL solution for injection
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
 
Link  NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
   
Infliximab (Remsima®, Inflectra®, Remicade®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for psoriasis in line with NICE.
 
Link  NICE TA134: Infliximab for psoriasis
   
Ixekizumab (Taltz®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for the treatment of moderate to severe plaque psoriasis in adults in line with NICE
 
Link  NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
   
Cytotoxic Drug Methotrexate
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber
 
   
Pimecrolimus cream (Elidel®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
  • Approved for moderate disease on face and neck for those between 2 and 16 years in line NICE.
 
Link  NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
   
Secukinumab (Cosentyx®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • Approved for the treatment of plaque psoriasis in line with NICE.
 
Link  NICE TA350: Plaque Psoriasis
Link  NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
   
Tacrolimus ointment (Protopic® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green plus
  • Approved for moderate to severe disease atopic eczema in patients over 2 years in line with NICE.
 
Link  NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
   
Ustekinumab (Stelara®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
  • 45mg & 90mg SC injections approved for psoriasis and psoriatic arthritis in line with NICE.
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE
 
Link  NICE TA180: Psoriasis - ustekinumab (Updated March 2017)
Link  NICE TA340: Ustekinumab for treating active psoriatic arthritis
Link  NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs for hospital use only. The responsibility for initiation and monitoring treatment should rest with an appropriate hospital clinician and the drug should be supplied through the hospital throughout the duration of treatment. In some very exceptional circumstances (e.g. due to distance from the hospital, storage, supply or mobility/transport problems) it may be appropriate for the GP to be asked to prescribe a Red drug. This should be negotiated on an individual patient basis and should only be done with the GP’s prior informed agreement where the roles of the GP and hospital services are clearly defined and agreed. The GP should not feel under pressure to prescribe in these circumstances.   

Amber

Drugs initiated by hospital specialist, but where continuing treatment by GPs may be appropriate under a shared care arrangement. The specialist should send the GP a copy of the shared care agreement to sign. The GP should sign the shared care agreement, or indicate they do not want to be part of such an agreement, and return a copy back to the specialist. Shared care guidelines are available or are being developed for most of the drugs listed as Amber. If no shared care guideline is available, the hospital specialist should provide the patient’s GP with sufficient information and support to allow treatment to be continued and managed safely in primary care.  

Green plus

Drugs normally recommended or initiated by hospital specialist, but where the provision of an information leaflet may be appropriate to facilitate continuing treatment by GPs. Many of these information sheets are in the process of development.  

Green

Drugs where prescribing by GPs is appropriate. Drugs not classified as Red, Amber or Green Plus (formerly blue in North of Tyne) are generally classified as ‘Green’ by default. The Green drugs listed here include those products normally initiated by hospital specialists where there was a need for discussion and debate as to the category in which they should be placed.  

netFormulary